Growth Hormone · GHRP

GHRP-6

GHRP-6 is a synthetic growth hormone-releasing peptide with significant appetite-stimulating effects due to its potent ghrelin-receptor activation. Used to increase GH and food intake.

Category: Growth Hormone Secretagogues Last updated 2026-06-19

GHRP-6 at a glance

GHRP-6 is a synthetic growth hormone-releasing peptide with significant appetite-stimulating effects due to its potent ghrelin-receptor activation. Used to increase GH and food intake. Mechanism: GHRP / GH secretagogue. Typical route: Subcutaneous. FDA status: Not FDA-approved. Dispensed by compounding pharmacies; less commonly used in modern protocols than Ipamorelin given the appetite effect.

Drug classGHRP / GH secretagogue

Half-life~30 minutes

RouteSubcutaneous

Common dosing100-200 mcg, 2-3x/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

GHRP-6 binds the ghrelin receptor (GHS-R1a) and stimulates pituitary GH release. Compared with GHRP-2, GHRP-6 has a stronger appetite-stimulating effect, which can be desirable for patients trying to gain weight but undesirable for body-composition goals.

Dosing reference

Subcutaneous: 100-200 mcg, two to three times daily. Often combined with CJC-1295 or modified GRF (1-29) for stronger and more sustained GH pulses.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Dispensed by compounding pharmacies; less commonly used in modern protocols than Ipamorelin given the appetite effect.

U.S. telehealth providers that work with GHRP-6

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates GHRP-6.

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates GHRP-6.

Read review →

#3 of 4

Maximus

76/100v3.0 six-pillar rubric

Starting at $149/mo. Maximus is one of the providers covered in our editorial directory that dispenses or coordinates GHRP-6.

Read review →

#4 of 4

Hone Health

80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates GHRP-6.

Read review →

Related growth hormone secretagogues peptides

Browse the full Growth Hormone Secretagogues category →

Frequently asked questions about GHRP-6

Does GHRP-6 cause hunger?

Yes. GHRP-6 has the strongest appetite-stimulating effect of the common GHRPs. This makes it useful for patients with poor appetite but unsuitable for weight-management goals.

What is the difference between GHRP-6 and Ipamorelin?

Ipamorelin is a 'cleaner' GH stimulator with minimal appetite, prolactin, or cortisol effects. Most modern protocols favor Ipamorelin (often combined with CJC-1295) over GHRP-6.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing